Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionize Brand Engagement: MSquared Puts Interoperability Center Stage in MLB’s Virtual Ballpark!26.9.2024 23:48:00 EEST | Press release
Solving the Interoperability Challenge MSquared’s demonstration is the first major showcase of how it has solved the technical challenges of metaverse interoperability. The integration of the Metaverse Markup Language (MML) lies at the heart of this success, offering a revolutionary way to define interactive 3D content that can seamlessly run across different virtual spaces and engines. Additionally, M² has developed a secure digital rights management and moderation system that allows IP owners and consumers to have appropriate protections as content moves freely between worlds. “MSquared has systematically overcome the challenges of interoperability - from ownership to standardized visualizations and secure asset storage,” said Rob Whitehead, Chief Product Officer of Improbable. “Our technology safeguards intellectual property and brand integrity across diverse virtual environments, ensuring seamless and secure experiences.” Elevate Your Brand in the Metaverse This milestone event in
Grid Dynamics Expands Global Footprint with JUXT Acquisition, Strengthening Expertise in Banking and Financial Services26.9.2024 23:05:00 EEST | Press release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announces its acquisition of JUXT, a UK-based provider of software engineering services specializing in data-intensive information systems for banking and other financial institutions, with a particular focus on risk platforms, structured notes, equity derivatives, and financial reporting. With this acquisition, Grid Dynamics adds significant expertise and capabilities to better serve enterprise clients in the financial services industry. Founded in 2013, JUXT is known for delivering complex end-to-end solutions, from design and user experience, to deep functionality and ongoing managed services. Their specializations in mission-critical platforms and products for leading banks and financial institutions make them a strategically important addition to Grid Dynamics, especially as global demand for reliable
BM3EAC Corp. 2024 Semi-Annual Report26.9.2024 21:58:00 EEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2024 to 30 June 2024. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
UCC Holding Ranked 42 nd in ENR’s Top International Contractors26.9.2024 21:32:00 EEST | Press release
Urbacon Holding, a leader in energy, concessions, and construction, announced its ranking as the 42nd top international contractor for 2024, according to Engineering News-Record (ENR). The company celebrated this achievement during the ConteQ Expo 2024 in Qatar, where it participated as the event's official sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926450701/en/ UCC Holding Ranked 42nd in ENR’s Top International Contractors (Photo: AETOSWire) The event brought together UCC Holding’s Board of Directors and senior management, who emphasized the company’s ongoing efforts to integrate advanced construction technologies into its operations. During the expo, UCC Holding introduced three innovative construction methods: 3D construction printing, concrete modular construction, and steel structure modular construction. These technologies are already being incorporated into UCC’s future projects, including a series of
Sinopec Awarded Best Environmental Protection Case at First Sino-European Corporate ESG Best Practice Conference26.9.2024 20:06:00 EEST | Press release
The ESG case from China’s Sinopec, titled “Empowering Green Development, Co-Creating a Zero-Carbon Future,” stood out from dozens of entries and was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926903754/en/ An ESG case from China’s Sinopec was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. (Photo: Business Wire) Walter Döring, Chairman of German World Market Leaders Association, on behalf of the event's organizing committee, announced the results. He stated, “Sinopec has demonstrated exceptional practical value in environmental protection. Through its comprehensive environmental management system and innovative technological means, as well as the use of cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom